Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

504P - Prognostic factors of patients with AFP-positive colorectal cancer: A case-control study

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Min-Yi Lv

Citation

Annals of Oncology (2021) 32 (suppl_5): S530-S582. 10.1016/annonc/annonc698

Authors

M. Lv, D. He, Y. Lin, Z. Chen, J. Chen, Z. Chi, T. Huang, X. Chen, X. He

Author affiliations

  • Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, 510655 - Guangzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 504P

Background

α-Fetoprotein-positive colorectal cancer (AFPP-CRC) is a rare type of colorectal cancer (CRC), and there have been no comprehensive investigations on prognostic factors of AFPP-CRC. The aim of this study was to elucidate the prognostic factors of AFPP-CRC.

Methods

During the years of 2010 to 2020, 127 CRC patients with preoperative elevated serum AFP level were collected, after excluding the diagnosis of hepatitis, hepatocirrhosis and hepatocarcinoma. The AFPP-CRC group control was matched by 1:2 to the AFPN(α-Fetoprotein-negative)-CRC group after propensity score matching (PSM) analysis. Prognostic factors were investigated using univariate and multivariate Cox regression model. Kaplan-Meier curves were performed among the prognostic factors as well.

Results

After PSM analysis, these two groups were balanced for age, sex, and tumor stage. After adjusting for other confounding factors, AFP positivity and tumor stage were shown to be associated with poorer overall survival (OS) and disease-free survival (DFS). The median of OS was 26.4 months versus 30.3 months when comparing AFPP-CRC group versus AFPN-CRC group. The median of disease-free survival was 23.3 months in the AFPP-CRC group, as compared to 26.0 months in the AFPN-CRC group. Among AFPP-CRC patients, those who also had a worse prognosis were characterized by elevated serum CEA level (P<0.001), liver metastasis(P<0.001), nerve infiltration(P=0.009), peritoneal metastasis(P=0.02), poorer stage(P<0.001) and microsatellite stability (P=0.007).

Conclusions

We found higher serum AFP level before surgery was associated with worse OS in patients with CRC, even adjusting for tumor stage. Besides, AFPP-CRC with microsatellite stability might had a worse prognosis.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.